DOCSLIB.ORG

Regulatory T Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulatory T Cells For more information, please visit our website at www.RnDSystems.com/go/Treg R&D Systems Products for Treg Cell Research PRSRT STD CELL SELECTION KITS* RECOMBINANT ELISAs/ ELISpot KITS* RECOMBINANT ELISAs/ U.S. POSTAGE R&D Systems Tools for Cell Biology Research™ MOLECULE ANTIBODIES ELISpot KITS* & NATURAL PROTEINS ASSAYS MOLECULE ANTIBODIES CELL SELECTION KITS* & NATURAL PROTEINS ASSAYS PAID 4-1BB/TNFRSF9/CD137 H M H M H M IFN-γ H M R B Ca H M R P Ca E F Pr H M R B Ca H M R B Ca 5’-Nucleotidase/CD73 H M H M CR E F P RM CR E F P RM CR E F P Pr USA & Canada IFN-γ R1/CD119 H M H M H M R&D Systems, Inc. R&D SYSTEMS B7-1/CD80 H M R H M R H M 4 4 10 61410 McKinley Place NE, Minneapolis, MN 55413 B7-2/CD86 H M R H M R R IFN-γ R2 H M 70 15 100 Tel: (800) 343-7475 (612) 379-2956 100 B7-H2 H M H M IGSF2/CD101 M Change Service Requested IL-1α/IL-1F1 H M R CR P H M R CR P H M R Fax: (612) 656-4400 60 E-Cadherin H M H M H M H M [email protected] 80 cAMP Ms Ms β H M R Ca 103 H M R Ca 103 80 IL-1 /IL-1F2 CR E F P H P CR E F P RM H M R F P 50 CCL1/I-309/TCA-3 H M H M H M MA104_Treg_NOV 10 IL-1 RI/CD121a H M H M R H 60 CCL4/MIP-1β H M Ca CR H M Ca CR H M 40 60 CCL17/TARC H M H M H M IL-1 RII/CD121b H M H M H H M R B Ca H M R B Ca H M R B Ca 2 30 CCL19/MIP-3β H M H M H M IL-2 H M R Ca E F102 10 40 LAP 40 CR E F P CD4 CR E F P E F 5 CCL20/MIP-3α H M R H M R H M R 20 IL-2 Rβ H M H Number Cell Relative Relative Cell Number Cell Relative CCL22/MDC H M H M H M Number Cell Relative Number Cell Relative Regulatory T Cells H M R B Ca H M R B Ca H M R CR 20 20 CCR2 H M IL-4 CR E F P H M Ca E CR E F P RM E F P 10 1 101 CCR4 H IL-4 Rα H M 10 H M CCR5 H H 0 0 0 0 H M R Ca H M R Ca H M R Ca 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 100 101 102 103 104 CCR6 H M IL-10 CR E F P V H M Ca F CR E F P V E F P 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 CD39 NRP-1 CCR7 H M IL-10 Rα H M H M GITR CTLA-4 100 Printed100 on recyclable paper 10% post consumer waste. IL-10 CCR8 H M R IL-10 Rβ H M 0 H 1 2 3 4 100 101 102 103 104 10 10 10 10 10 R&D Systems is a registered trademark of TECHNE Corporation. CD3 H M H M R IL-35 p35 H M P CD127 CD25 Latent TGF-β1 CD3e H M Integrin αE/CD103 M LRRC32 CD4 H M Ca F H M R H Integrin αEβ7 H Galectin-1 CD5 H M Integrin αL/CD11a H + + ™ CD25/IL-2 Rα H M R H M R H M R H M Integrin αVβ8 H CD4 CD25 Regulatory T Cell Enrichment using MagCellect Cell Selection Kits 4 CD27/TNFRSF7 H M H M M Integrin β2/CD18 H M H R&D Systems offers MagCellect Cell Selection Kits for human, mouse, or rat CD4+CD25+ Treg cell isolation. A. 10 CD27 Ligand/TNFSF7 H M M M Jak1 H M R The MagCellect Kits are designed to isolate CD4+CD25+ Treg cells from a mononuclear cell suspension FoxP3 CD127/IL-7 Rα H M R H M R M Jak3 H IL-35 + + CD28 H M H M LAG-3 H M 80 H H using a two-step100 procedure. CD4 T cells are initially enriched by negative selection. CD25 T cells are then 3 Regulatory T Cell CD30/TNFRSF8 H M H M M LAP (TGF-β1) H M H isolated by positive selection from the CD4+ T cell fraction. The90 typical purity of the recovered CD4+CD25+ 10 70 CD30 Ligand/TNFSF8 H M H M M LRRC32/GARP M H M 80 Treg cells ranges80 between 85-95% for the human kit, 84-94% for the mouse kit, and 75-85% for the rat kit. CD34 R P Ca MAdCAM-1 M 60 M M 70 IL-2 Rβ CD38 H M H M Neuropilin-1/BDCA4 H M R H M R TGF-β1 50 MagCellect KIT CATALOG # 60 KIT CONTENTS 102 CD39/ENTPD1 H M H M OX40/TNFRSF4 H M H M 60 IL-2 Rα/CD25 + + + CD25 IL-2 Rγ CD40/TNFRSF5 H M H M M OX40 Ligand/TNFSF4 H M 40 H M M Human CD4 CD25 Regulatory T Cell Isolation Kit MAGH104 Human CD4 T Cell50 Biotinylated Antibody Cocktail, Streptavidin Ferrofluid, Anti-Human CD25 Ferrofluid (Clone 24238), 10X Buffer, Staining Reagent for CD40 Ligand/TNFSF5 H M H M H M 40 PD-1 H M 30 H M H 40 Human CD4+CD25+ Regulatory T Cells CD44 H Ca H H PDCD6 H M R 30 1 + + + 10 CD45 H M H H M H PD-L1/B7-H1 H M Number Cell Relative 20 H M Mouse CD4 CD25 Number Cell Relative Regulatory T Cell Isolation Kit MAGM208 Mouse CD4 T Number Cell Relative Cell Biotinylated Antibody Cocktail, Streptavidin Ferrofluid, 20 Mouse CD25 Biotinylated20 Antibody (Clone PC61.5), 10X Buffer CD45R/B220 M PD-L2 H M H M 10 10 CD69 H M PRAT4A M Rat CD4+CD25+ Regulatory T Cell Isolation Kit MAGR304 Rat CD4 T Cell Antibody Cocktail, Anti-Mouse IgG Ferrofluid, Streptavidin CD72 M PRAT4B M R 0 0 Ferrofluid, Rat CD250 Biotinylated Antibody, 10X Buffer 100 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 Effector T Cells CD83 H M H M RANK/TNFRSF11A H M 10 H M 10 10 H 10 10 10 10 10 10 10 10 10 10 10 10 100 101 102 103 104 CD109 H H RARa/NR1B1 H IL-12/p35 Assay Principle LAG-3 CD27 CD4 γ Common Chain/IL-2 H M H M c-Rel H M H Rγ RXRα/NR2B1 H ENRICHMENT OF CD4+ T CELLS ENRICHMENT OF CD4+ CD25+ T CELLS B. 104 CREB H M R H M R E-Selectin/CD62E H M R H M H M CTLA-4 H M H M M CD4 Biotinylated CD25 Antibody L-Selectin/CD62L H M R H M R H M R Antibody Cocktail Anti-CD25 Ferrouid or CXCL9/MIG H M H H M H M P-Selectin/CD62P H M H M H M Streptavidin Ferrouid + Streptavidin Ferrouid 3 CXCL10/IP-10/CRG-2 H M CR H H M CR H M SLAM/CD150 H M M or Anti-IgG Ferrouid Enriched Enriched 10 + + + CXCL12/SDF-1 H M H M F RM H M Smad3 H M H CD4 T Cells CD4 CD25 T Cells CXCR3 H M STAT5a, STAT5b H M CXCR4 H M F H TGF-β1 H M Ms H H P H M R Ca P 102 Fas/TNFRSF6/CD95 H M R F H M R F H M TGF-β RI/ALK-5 H M M CD25 FoxP3 H M R H TGF-β RII H M H M H Galectin-1 H M H M M TGF-β RIIb H H GITR/TNFRSF18 H M H M H M TLR4 H M H 101 GITR Ligand/TNFSF18 H M H M H M TLR4/MD-2 Complex H Granzyme A H H TLR7 H Granzyme B H M H M H M M TNF RII/TNFRSF1B H M H M H M 0 HLA-DR H TOR H M R H 10 100 101 102 103 104 HO-1/HMOX1/HSP32 H M R H TRAIL/TNFSF10 H M H M H KEY: Undesired cells CD4+ T Cells CD4+CD25+ T Cells ICAM-1/CD54 H M R H M R H M R CD4 TRANCE/TNFSF11/RANK H M H M M ICOS H M H M L Enrichment of CD4+CD25+ T cells using the MagCellect CD4+CD25+ Regulatory T Cell Isolation Kits. The CD4 Antibody Cocktail is added to a mononuclear cell suspension. Undesired Enrichment of CD4+CD25+ Treg Cells using the MagCellect Kits. CD4+CD25+ Treg IDO H TSLP H M H M H M cells are bound by the antibodies and then captured by MagCellect Ferrofluid magnetic particles, or equivalent. The undesired cells are isolated from the sample by negative selection cells were isolated from (A) human PBMCs using the MagCellect Human CD4+CD25+ IFN-α H M P CR H M R CR F P RM H M TSLP R H M H M using a MagCellect Magnet (Catalog # MAG997), or equivalent, and an enriched CD4+ T cell population is aspirated from the sample solution.
Load more

Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Our Immune System (Children's Book)
    OurOur ImmuneImmune SystemSystem A story for children with primary immunodeficiency diseases Written by IMMUNE DEFICIENCY Sara LeBien FOUNDATION A note from the author The purpose of this book is to help young children who are immune deficient to better understand their immune system. What is a “B-cell,” a “T-cell,” an “immunoglobulin” or “IgG”? They hear doctors use these words, but what do they mean? With cheerful illustrations, Our Immune System explains how a normal immune system works and what treatments may be necessary when the system is deficient. In this second edition, a description of a new treatment has been included. I hope this book will enable these children and their families to explore together the immune system, and that it will help alleviate any confusion or fears they may have. Sara LeBien This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SECOND EDITION COPYRIGHT 1990, 2007 IMMUNE DEFICIENCY FOUNDATION Copyright 2007 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Our Immune System may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 40 West Chesapeake Avenue, Suite 308, Towson, MD 21204, USA; or by telephone at 1-800-296-4433.
    [Show full text]
  • Chronic Myeloid Leukemia: Mechanisms of Blastic Transformation
    Chronic myeloid leukemia: mechanisms of blastic transformation Danilo Perrotti, … , John Goldman, Tomasz Skorski J Clin Invest. 2010;120(7):2254-2264. https://doi.org/10.1172/JCI41246. Science in Medicine The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid leukemia (CML). Patients with early phase (also known as chronic phase [CP]) disease usually respond to treatment with ABL tyrosine kinase inhibitors (TKIs), although some patients who respond initially later become resistant. In most patients, TKIs reduce the leukemia cell load substantially, but the cells from which the leukemia cells are derived during CP (so-called leukemia stem cells [LSCs]) are intrinsically insensitive to TKIs and survive long term. LSCs or their progeny can acquire additional genetic and/or epigenetic changes that cause the leukemia to transform from CP to a more advanced phase, which has been subclassified as either accelerated phase or blastic phase disease. The latter responds poorly to treatment and is usually fatal. Here, we discuss what is known about the molecular mechanisms leading to blastic transformation of CML and propose some novel therapeutic approaches. Find the latest version: https://jci.me/41246/pdf Science in medicine Chronic myeloid leukemia: mechanisms of blastic transformation Danilo Perrotti,1 Catriona Jamieson,2 John Goldman,3 and Tomasz Skorski4 1Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA. 2Division of Hematology-Oncology, Department of Internal Medicine, University of California at San Diego, La Jolla, California, USA. 3Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom. 4Department of Microbiology and Immunology, Temple University, Philadelphia, Pennsylvania, USA.
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • Recombinant Mouse IGSF2/CD101 Fc Chimera Catalog Number: 3368-CD
    Recombinant Mouse IGSF2/CD101 Fc Chimera Catalog Number: 3368-CD DESCRIPTION Source Mouse myeloma cell line, NS0-derived mouse IGSF2/CD101 protein Mouse CD101 Mouse IgG (Gln21-Phe974) IEGRMDP 2a (Glu98-Lys330) Accession # A8E0Y8 N-terminus C-terminus N-terminal Sequence No results obtained. Gln21 inferred from enzymatic pyroglutamate treatment revealing Arg22. Analysis Structure / Form Disulfide-linked homodimer Predicted Molecular 133 kDa Mass SPECIFICATIONS SDS-PAGE 121-150 kDa, reducing conditions Activity Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED50 for this effect is 1.4-8.4 μg/mL. Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. Formulation Lyophilized from a 0.2 μm filtered solution in PBS. See Certificate of Analysis for details. PREPARATION AND STORAGE Reconstitution Reconstitute at 400 μg/mL in PBS. Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, ≤ -20 °C under sterile conditions after reconstitution. DATA Bioactivity SDS-PAGE Recombinant Mouse 2 μg/lane of Recombinant Mouse IGSF2/CD101 was resolved with IGSF2/CD101 Fc Chimera SDS-PAGE under reducing (R) and non-reducing (NR) conditions (Catalog # 3368-CD) inhibits and visualized by Coomassie® Blue staining, showing bands at anti-CD3 antibody induced 121-150 kDa and 240-280 kDa, respectively.
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,005,612 B2 Ledbetter Et Al
    US009005612B2 (12) United States Patent (10) Patent No.: US 9,005,612 B2 Ledbetter et al. (45) Date of Patent: *Apr. 14, 2015 (54) BINDING DOMAIN-IMMUNOGLOBULIN 5,455,030 A 10/1995 Ladner et al. FUSION PROTEINS $599. A 3: BestInsley et al. al. (75) Inventors: Jeffrey A. Ledbetter, Seattle, WA (US); 5,530,101 A 6/1996 Queen et al. Martha S. Hayden-Ledbetter, Seattle, 5,580,756. A 12/1996 Linsley et al. WA (US) 5,595,7215,585,089 A 1431/1997 SAS,Kaminski et al.1 (73) Assignee: Emergent Product Development 5,597,707 A 1/1997 Marken et al. Seattle, LLC, Seattle, WA (US) 3.W - A 3.87 EaCee ea. (*) Notice: Subject to any disclaimer, the term of this 5,645,835 A 7/1997 Fell, Jr. et al. patent is extended or adjusted under 35 $22.9 A ck 8. 3. Earl 530,387.1 U.S.C. 154(b) by 0 days. 5,693,762.w A 12/1997 QueenOCC et Cal. al. ............ This patent is Subject to a terminal dis- 5,709,859 A 1/1998 Aruffo et al. claimer 5,714,147 A 2, 1998 Capon et al. 5,721, 108 A 2f1998 Robinson et al. (21) Appl. No.: 13/451,641 5,736,137 A 4, 1998 Anderson et al. 5,770,197 A 6/1998 Linsley et al. (22) Filed: Apr. 20, 2012 5,773.253 A 6/1998 Linsley et al. O O 5,776.456 A 7/1998 Anderson et al. (65) Prior Publication Data 5,795,572 A 8/1998 Diegel et al.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • A Novel BCMA/CD3 Bispecific T-Cell Engager for the Treatment
    OPEN Leukemia (2017) 31, 1743–1751 www.nature.com/leu ORIGINAL ARTICLE A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp1, Y-T Tai2,3, D Blanset4, P Deegen5, J Wahl5, O Thomas5, B Rattel5, PJ Adam1, KC Anderson2,3 and M Friedrich5 B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ε (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA- positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/ refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.
    [Show full text]
  • Regulatory Lymphocytes: the Dice That Resolve the Tumor Endgame Subhadip Pati, Anandi Chowdhury, Sumon Mukherjee, Aharna Guin, Shravanti Mukherjee and Gaurisankar Sa*
    Pati et al. Applied Cancer Research (2020) 40:7 Applied Cancer Research https://doi.org/10.1186/s41241-020-00091-0 REVIEW Open Access Regulatory lymphocytes: the dice that resolve the tumor endgame Subhadip Pati, Anandi Chowdhury, Sumon Mukherjee, Aharna Guin, Shravanti Mukherjee and Gaurisankar Sa* Abstract A large number of cancer patients relapse after chemotherapeutic treatment. The immune system is capable of identifying and destroying cancer cells, so recent studies have highlighted the growing importance of using combinatorial chemotherapy and immunotherapy. However, many patients have innate or acquired resistance to immunotherapies. Long-term follow-up in a pooled meta-analysis exhibited long-term survival in approximately 20% of patients treated with immune checkpoint inhibitors or the adoptive transfer of chimeric T cells. It has been reported that high levels of immunoregulatory cells in cancer patients contribute to immunotherapy resistance via immunosuppression. Among the most important regulatory cell subtypes are the CD4+ T-regulatory cells (Tregs), identified by their expression of the well-characterized, lineage-specific transcription factor FOXP3. In addition to CD4+ Tregs, other regulatory cells present in the tumor microenvironment, namely CD8+ Tregs and IL10-producing B-regulatory cells (Bregs) that also modulate the immune response in solid and lymphoid tumors. These cells together have detrimental effects on tumor immune surveillance and anti-tumor immunity. Therefore, targeting these regulatory lymphocytes will be crucial in improving treatment outcomes for immunotherapy. Keywords: Breg, CTLA4, FOXP3, Immunotherapy, IL10, PDL1, Treg Background neo-antigens, which are not present in non-cancerous The suppression of anti-tumor immune responses and cells [5]. These neo-antigens offer a clinical advantage augmentation of tumor-promoting immune responses since the tumor cells expressing neo-antigens are then both contribute to tumor progression [1].
    [Show full text]
  • Atpase, Na+/K+ Transporting, Alpha 3 Polypeptide Homologous to 3'UTR
    HUGO ID Name Nalm-6 TOM-1 Reh Karpas-422 DoHH -2 SU-DHL-5 Namalwa DG-75 Ramos Raji BEL EHEB BONNA-12 L-428 DEL BCP-1 BC-3 BCBL-1 JSC-1 PEL-SY HBL-6 DS-1 RPMI-8226 NCI-H929 L-363 SK-MM-2 ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide CD24 homologous to 3'UTR of human CD24 gene ABCC5 multidrug resistance-associated protein (MRP5) CD72 CD72 antigen TCL1A Tcell leukemia/lymphoma 1 ITGB2 Integrin, beta 2 (antigen CD18 (p95)) ? nuclear ribonucleoprotein particle (hnRNP) SGT1 suppressor of G2 allele of skp1 homolog DNMT 1 DNA (cytosine-5-)-methyltransferase 1 GALE UDP-Galactose 4 epimerase (GALE) HADHSC L-3-hydroxyacyl-CoA dehydrogenase LIG4 DNA ligase IV LIG1 Ligase I, DNA, ATP-dependent CEBPG CCAA T/enhancer binding protein (C/EBP), gamma DCK Deoxycytidine kinase TCEA1 TRANSCRIPTION ELONGATION FACTOR S-II TCN 1 TRANSCOBALAMIN I PRECURSOR POLA2 DNA polymerase alpha subunit CCNG2 cyclin G2 RNPC1 Finkel-Biskis-Reilly murine sarcoma virus; Human seb4D RNPC1 Finkel-Biskis-Reilly murine sarcoma virus; Human seb4D DGKD Diacylglycerol kinase delta KIAA0220 Polycystic kidney disease protein 1 KIAA0220 calcium-dependent group X phospholipase A2 KIAA0220 calcium-dependent group X phospholipase A2 ALDH5A1 NAD+-dependent succinate-semialdehyde dehydrogenase CCNG2 Polycystic kidney disease 1 (autosomal dominant) PDCD4 nuclear antigen H731-like protein SSH3BP1 eps8 binding protein e3B1 MAP4K2 B lymphocyte serine/threonine protein kinase (GC kinase) MAPRE2 novel T-cell activation protein ZNFN1A Ikaros/LyF-1 homolog (hIk-1) FLJ22624 clone 23799 KIAA0355
    [Show full text]